Florence Canouï‐Poitrine

Prof. Dr. Florence Canouï‐Poitrine


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
JRJean E. Revuz
Jean E. Revuz
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
PWPierre Wolkenstein
Pierre Wolkenstein
CVCedric Viallette
Cedric Viallette
GGGermaine Gabison
Germaine Gabison
SBSylvie Bastuji-Garin
Sylvie Bastuji-Garin

20 September 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PCPhilippe Caillet
Philippe Caillet
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
JVJohanna Vouriot
Johanna Vouriot
MBMuriel Berle
Muriel Berle
NRNicoleta Reinald
Nicoleta Reinald
Éléna PaillaudÉléna Paillaud
Éléna Paillaud
Purpose: To identify Comprehensive Geriatric Assessment (CGA) components independently associated with changes in planned cancer treatment. Patients and Methods: We prospectively included 375 consecutive elderly patients with cancer (ELCAPA01 study) assessed by geriatricians using the CGA. Multivariate analysis was used to identify factors associated with changes in the cancer treatment (intensification, decrease, or delayed > 2 weeks). Change was defined as a difference between the initial treatment proposal and the final treatment selected in a multidisciplinary meeting. Results: Mean age was 79.6 years (standard deviation [SD], 5.6 years), and 197 (52.5%) were women. The most common tumor location was the digestive system (58.7%). The mean number of comorbidities was 4.2 (SD, 2.7) per patient, and the mean Cumulative Illness Rating Scale for Geriatrics score was 11.8 (SD, 5.3). After the CGA, the initial cancer treatment plan was modified for 78 (20.8%) of 375 patients (95% CI, 16.8 to 25.3), usually to decrease treatment intensity (63 [80.8%] of 78 patients). By univariate analysis, cancer treatment changes were associated with Eastern Cooperative Oncology Group performance status ≥ 2 (73.3% in the group with changes v 41.1% in the in the group without changes; P < .001), dependency for one or more activities of daily living (ADL; 59.0% v 24.2%; P < .001), malnutrition (81.8% v 51.2%; P < .001), cognitive impairment (38.5% v 24.9%; P = .023), depression (52.6% v 21.7%; P < .001), and greater number of comorbidities (mean, 4.8 [SD, 2.9] v 4.0 [SD, 2.6]; P = .02). By multivariate analysis, factors independently associated with cancer treatment changes were a lower ADL score (odds ratio [OR], 1.25 per 0.5-point decrease; CI, 1.04 to 1.49; P = .016) and malnutrition (OR, 2.99; CI, 1.36 to 6.58; P = .007). Conclusion: Functional status assessed by the ADL score and malnutrition were independently associated with changes in cancer treatment.

15 January 2012 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JRJean-Paul Richalet
Jean-Paul Richalet
PLPhilippe Larmignat
Philippe Larmignat
EPEric Poitrine
Eric Poitrine
MLMurielle Letournel
Murielle Letournel
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
Rationale: An increasing number of persons, exposed to high altitude for leisure, sport, or work, may suffer from severe high-altitude illness. Objectives: To assess, in a large cohort of subjects, the association between physiological parameters and the risk of altitude illness and their discrimination ability in a risk prediction model. Methods: A total of 1,326 persons went through a hypoxic exercise test before a sojourn above 4,000 m. They were then monitored up at high altitude and classified as suffering from severe high-altitude illness (SHAI) or not. Analysis was stratified according to acetazolamide use. Measurements and Main Results: Severe acute mountain sickness occurred in 314 (23.7%), high-altitude pulmonary edema in 22 (1.7%), and high-altitude cerebral edema in 13 (0.98%) patients. Among nonacetazolamide users (n = 917), main factors independently associated with SHAI were previous history of SHAI (adjusted odds ratios [aOR], 12.82; 95% confidence interval [CI], 6.95–23.66; P < 0.001), ascent greater than 400 m/day (aOR, 5.89; 95% CI, 3.78–9.16; P < 0.001), history of migraine (aOR, 2.28; 95% CI, 1.28–4.07; P = 0.005), ventilatory response to hypoxia at exercise less than 0.78 L/minute/kg (aOR, 6.68; 95% CI, 3.83–11.63; P < 0.001), and desaturation at exercise in hypoxia equal to or greater than 22% (aOR, 2.50; 95% CI, 1.52–4.11; P < 0.001). The last two parameters improved substantially the discrimination ability of the multivariate prediction model (C-statistic rose from 0.81 to 0.88; P < 0.001). Preventive use of acetazolamide reduced the relative risk of SHAI by 44%. Conclusions: In a large population of altitude visitors, chemosensitivity parameters (high desaturation and low ventilatory response to hypoxia at exercise) were independent predictors of severe high-altitude illness. They improved the discrimination ability of a risk prediction model.

1 July 2009 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
JRJean E. Revuz
Jean E. Revuz
PWPierre Wolkenstein
Pierre Wolkenstein
CVCédric Viallette
Cédric Viallette
GGGermaine Gabison
Germaine Gabison
SBSylvie Bastuji-Garin
Sylvie Bastuji-Garin

8 July 2009 in Dermatology
Verified
Journal Article
Open access
PDF file
GGG. Gener
G. Gener
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
JRJ.E. Revuz
J.E. Revuz
OFO. Faye
O. Faye
FPF. Poli
F. Poli
SBSylvie Bastuji-Garin
Sylvie Bastuji-Garin
Background: Antibiotics are frequently used to treat hidradenitis suppurativa (HS); however, few data on their efficacy are available. Objective: To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS. Methods: Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment. Results: The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects. Conclusion: The combination of clindamycin and rifampicin is effective in the treatment of severe HS.

1 June 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
ATAurélie Le Thuaut
Aurélie Le Thuaut
JRJean E. Revuz
Jean E. Revuz
CVCédric Viallette
Cédric Viallette
GGGermaine Gabison
Germaine Gabison
SBSylvie Bastuji-Garin
Sylvie Bastuji-Garin